Somewhat Positive Media Coverage Somewhat Unlikely to Impact Strongbridge Biopharma (SBBP) Stock Price

News stories about Strongbridge Biopharma (NASDAQ:SBBP) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Strongbridge Biopharma earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 45.9902215619421 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

These are some of the news stories that may have impacted Accern Sentiment Analysis’s analysis:

How to Become a New Pot Stock Millionaire

Strongbridge Biopharma stock traded down $0.20 during mid-day trading on Thursday, hitting $8.30. 178,996 shares of the company’s stock were exchanged, compared to its average volume of 310,366. The company has a debt-to-equity ratio of -3.17, a current ratio of 4.88 and a quick ratio of 4.84. The company has a market capitalization of $386.83, a price-to-earnings ratio of -5.72 and a beta of 0.99. Strongbridge Biopharma has a 1-year low of $3.50 and a 1-year high of $9.25.

Strongbridge Biopharma (NASDAQ:SBBP) last posted its earnings results on Monday, March 12th. The biotechnology company reported ($0.34) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.34). The business had revenue of $2.98 million for the quarter, compared to analyst estimates of $2.98 million. sell-side analysts anticipate that Strongbridge Biopharma will post -1.52 earnings per share for the current year.

Several analysts recently issued reports on the company. BidaskClub lowered Strongbridge Biopharma from a “strong-buy” rating to a “buy” rating in a report on Wednesday. Zacks Investment Research lowered Strongbridge Biopharma from a “buy” rating to a “hold” rating in a report on Wednesday, January 17th. Cantor Fitzgerald set a $14.00 price objective on Strongbridge Biopharma and gave the stock a “buy” rating in a report on Wednesday, January 17th. Finally, HC Wainwright reiterated a “buy” rating and set a $18.00 price objective on shares of Strongbridge Biopharma in a report on Thursday, January 18th. Two equities research analysts have rated the stock with a sell rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $12.81.

COPYRIGHT VIOLATION WARNING: This story was reported by BBNS and is the property of of BBNS. If you are accessing this story on another publication, it was stolen and republished in violation of United States and international trademark & copyright laws. The original version of this story can be accessed at https://baseballnewssource.com/2018/04/05/strongbridge-biopharma-sbbp-given-daily-coverage-optimism-rating-of-0-15/2027622.html.

Strongbridge Biopharma Company Profile

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.

Insider Buying and Selling by Quarter for Strongbridge Biopharma (NASDAQ:SBBP)

Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Red Sox Tie Record for Best Start After 17 Games
Red Sox Tie Record for Best Start After 17 Games
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Rick Porcello’s Strong Start Gives Boost to Red Sox
Rick Porcello’s Strong Start Gives Boost to Red Sox
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Xander Bogaerts Goes on Red Sox DL
Xander Bogaerts Goes on Red Sox DL


Leave a Reply

 
© 2006-2018 BBNS.